» Articles » PMID: 31808058

Histone Deacetylase Modifications by Probiotics in Colorectal Cancer

Overview
Publisher Springer
Date 2019 Dec 7
PMID 31808058
Citations 14
Authors
Affiliations
Soon will be listed here.
Abstract

It has been demonstrated that epigenetic modifications of histone (acetylation/deacetylation) participate in a critical role in cancer progression by the regulation of gene expression. Several processes could be regulated by deacetylation of histone and non-histone proteins such as apoptosis, proliferation, cell metabolism, differentiation, and DNA repair. Hence, histone deacetylase inhibitors (HDACis) are employed as a hopeful group of anti-cancer drugs that could inhibit tumor cell proliferation or apoptosis. The elimination of the acetylation marks that take place as an essential epigenetic change in cancer cells is associated to HDAC expression and activity. In this regard, it has been reported that class I HDACs have a vital role in the regulation of tumor cell proliferation. OBJECTIVES: In this review, we discuss whether gut origin microorganisms could promote cancer or tumor resistance and explain mechanisms of these processes. CONCLUSIONS: According to the enormous capacity of the metabolism of the intestine microbiota, bacteria are likely to convert nutrients and digestive compounds into metabolites that regulate epigenetic in cancer. The effect of the food is of interest on epigenetic changes in the intestinal mucosa and colonocytes, as misleading nucleotide methylation may be a prognostic marker for colorectal cancer (CRC). Since epigenetic changes are potentially reversible, they can serve as therapeutic targets for preventing CRC. However, various mechanisms have been identified in the field of prevention, treatment, and progression of cancer by probiotics, which include intestinal microbiota modulation, increased intestinal barrier function, degradation of potential carcinogens, protective effect on intestinal epithelial damage, and increased immune function.

Citing Articles

Microbiome structure in healthy and pregnant women and importance of vaginal dysbiosis in spontaneous abortion.

Eslami M, Naderian R, Ahmadpour A, Shushtari A, Maleki S, Mohammadian P Front Cell Infect Microbiol. 2025; 14:1401610.

PMID: 40046910 PMC: 11881085. DOI: 10.3389/fcimb.2024.1401610.


Effect of probiotics combined with immune checkpoint suppressors and chemotherapeutic agents on digestive system function, intestinal immunity and prognosis in patients with metastatic colorectal carcinoma: a quasi-experimental study.

Wang X, Huang Y, Yang Z, Yang Y, Wei F, Yan M BMC Gastroenterol. 2025; 25(1):38.

PMID: 39871150 PMC: 11773699. DOI: 10.1186/s12876-025-03604-9.


Using New Technologies to Analyze Gut Microbiota and Predict Cancer Risk.

Hemmati M, Monemi M, Asli S, Mohammadi S, Foroozanmehr B, Haghmorad D Cells. 2024; 13(23).

PMID: 39682735 PMC: 11640725. DOI: 10.3390/cells13231987.


Harmony unveiled: Intricate the interplay of dietary factor, gut microbiota, and colorectal cancer-A narrative review.

Endale H, Tesfaye W, Hassen F, Asrat W, Temesgen E, Yimer Shibabaw Y SAGE Open Med. 2024; 12:20503121241274724.

PMID: 39224896 PMC: 11367611. DOI: 10.1177/20503121241274724.


Microbial Metabolites-induced Epigenetic Modifications for Inhibition of Colorectal Cancer: Current Status and Future Perspectives.

Singh V, Shirbhate E, Kore R, Vishwakarma S, Parveen S, Veerasamy R Mini Rev Med Chem. 2024; 25(1):76-93.

PMID: 38982701 DOI: 10.2174/0113895575320344240625080555.